Fri, Jan 30, 2015, 12:10 AM EST - U.S. Markets open in 9 hrs 20 mins

Recent

% | $
Quotes you view appear here for quick access.

Oshkosh Corporation Message Board

delmur 5 posts  |  Last Activity: Jan 12, 2015 7:08 PM Member since: Jun 7, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • delmur delmur Jan 12, 2015 7:08 PM Flag

    Conjecture I agree and said as much in my thread. Baseless and unlikely is your opinion. This is taken from the FDA site on Biosimilars

    The Patient Protection and Affordable Care Act (Affordable Care Act), signed into law by President Obama on March 23, 2010, amends the Public Health Service Act (PHS Act) to create an abbreviated licensure pathway for biological products that are demonstrated to be “biosimilar” to or “interchangeable” with an FDA-licensed biological product. This pathway is provided in the part of the law known as the Biologics Price Competition and Innovation Act (BPCI Act). Under the BPCI Act, a biological product may be demonstrated to be “biosimilar” if data show that, among other things, the product is “highly similar” to an already-approved biological product.

    Health care professionals and consumers can be assured that FDA will require licensed biosimilar and interchangeable biological products to meet the Agency’s exacting standards of safety and efficacy.

  • delmur delmur Jan 12, 2015 5:57 PM Flag

    i'm sorry but I still find it troubling and very ironic that the FDA chose to do this at the very same time that TKMR and Oncore merges for only one disease, HBV. It just seems like imho that politics and influence were used here to get the FDA to slow down ARWR's progress so they can catch up. That and the fact that ARWR chose to go outside the FDA to do their studies first, and for good reasons I thought. Unfortunately it looks like Anzalone thought he could get it through FDA faster by doing it this way, and I thought it would be getting fast tracked soon myself.
    This disease is not as prevalent in the US as in ASIA, so FDA has an excuse to delay. I think it's good that ARWR is continuing on in Europe and Asia and I hope they embarrass the FDA, who has been saying in recent moths that they want to start getting new drugs out to the public faster. I just am confused by what happened today.

  • delmur delmur Jan 12, 2015 12:22 PM Flag

    I'm wondering if FDA is sticking it to ARWR because they went to Europe and Asia first to do the testing....seems to me like they want to slow them down for some reason.

  • Reply to

    will see $6.50 today

    by sullivancountyisgarbage Dec 16, 2014 8:29 AM
    delmur delmur Dec 16, 2014 10:30 AM Flag

    any comments on how you analyzed this uptrend?...tia

  • Reply to

    This Is All Really Crazy, But ...

    by mcjdog Dec 11, 2014 10:11 PM
    delmur delmur Dec 15, 2014 10:03 AM Flag

    What I can't understand is why this is having no effect on BG's share price. I realize that they are much more than just Moema, but you would think there would be some impact. And yet BG keeps going up and up. And their website mentions nothing about the project that I can see.
    Any thoughts?

OSK
43.14-1.34(-3.01%)Jan 29 4:04 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Core Laboratories NV
NYSEThu, Jan 29, 2015 4:00 PM EST
QUALCOMM Incorporated
NASDAQThu, Jan 29, 2015 4:00 PM EST